




Expert Forum on

CHRONIC LYMPHOCYTIC LEUKEMIA

JULY
26-27,
2019
DALLAS, TX



INVITED CHAIR:

STEVEN COUTRÉ, MD

Professor of Medicine
Stanford University Medical Center
Stanford, CA

Expert Forum on CHRONIC LYMPHOCYTIC LEUKEMIA

JULY 26-27, 2019
DALLAS, TX

Friday, July 26, 2019

4:30 PM Welcome and Introductions

THE BIOLOGY OF CLL

4:50 PM Prognostic Markers in the Era of Novel Therapeutics

5:00 PM Changes in Transcriptomics During Combination Therapy in CLL

CLINICAL TRIAL DESIGN IN CLL

5:40 PM Integrating MRD into Management of Patients with CLL

5:50 PM Identification of Early-stage, High-risk Patients Using CLL-IPI

6:00 PM Defining Precision Medicine in Newly-diagnosed and R/R CLL Patients

6:20 PM FCR vs Ibrutinib: When, Where, and Why?

6:30 PM [DISCUSSION](#)

7:00 PM [ADJOURN TO RECEPTION](#)

Saturday, July 27, 2019

7:00 AM [BREAKFAST](#)

TARGETING APOPTOSIS PATHWAYS IN CLL

8:00 AM Venetoclax in CLL: Practical Considerations

8:10 AM Rational Combinations of Venetoclax

8:20 AM [DISCUSSION](#)

PRACTICAL CONSIDERATIONS FOR IBRUTINIB

8:40 AM Depth and Durability of Response to Ibrutinib in CLL

8:50 AM Analyzing the Impact of Co-morbidities on the Efficacy of Ibrutinib

9:00 AM Emerging Role of BCR Signaling Inhibitors in Immunomodulation of CLL

9:10 AM Clonal Evolution Underlying Richter Transformation in Patients with Ibrutinib-relapsed CLL

9:20 AM [DISCUSSION](#)

9:50 AM [BREAK](#)

MOVING BEYOND IBRUTINIB TREATMENT IN CLL

10:00 AM Complications of BTK Therapy

10:10 AM AXL Receptor Tyrosine Kinase as a Unique Target in CLL

10:20 AM Vecabrutinib

10:30 AM Emerging Agent Showcase

10:40 AM Emerging Agent Showcase

10:50 AM [DISCUSSION](#)

NOVEL THERAPIES IN CLL

11:20 AM An Overview of PI3K Inhibitors in the Treatment of CLL

11:30 AM Targeting PI3K Isoforms: What Works Best?

11:40 AM Management of Patients Intolerant to Kinase Inhibitor Therapy

11:50 AM Integration of Novel Antibodies into the Treatment of CLL

12:00 PM [DISCUSSION](#)

12:30 PM [LUNCH](#)

CELLULAR THERAPIES IN CLL

1:30 PM What is the Role of CAR-T in CLL Treatment?

1:40 PM CD19 CAR-T Cells in CLL

1:50 PM High-risk CLL: Optimal Sequencing of Novel Agents, CAR-T Therapy, and Allogenic Stem Cell Transplantation

2:00 PM Umbilical and Cord Blood-derived CAR-engineered NK Cells

2:10 PM The Role of Transplantation in CLL

2:20 PM [DISCUSSION](#)

3:00 PM [ADJOURN](#)